CLLS · Cellectis S.A.

Summary

Cellectis presents preclinical data on a TALE-based epigenetic editing platform at ASGCT, demonstrating >90% gene knockdown without DNA breaks.

Key takeaways

• TALE-based epigenetic modulators (TALEM) achieve >90% sustained gene knockdown in T-cells and hepatocytes.
• The approach does not cut or modify DNA, potentially offering a safer alternative to traditional gene editing.
• Cellectis developed a high-throughput screening system to rapidly test hundreds of TALEM combinations.
• The platform targets genes implicated in T-cell dysfunction and liver cell activity, relevant to cancer immunotherapy.
• Data presented at ASGCT annual meeting (May 11-15, 2026) in Boston.